10 completed, 3 unknown, 2 recruiting, 2 terminated. 10 Phase 1, 5 Phase 2, 3 Not applicable, 1 Early Phase 1.
Follow Translational Drug Development: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MTX-531-001 Phase 1 Study in Advanced Solid Tumors MTX-531 - Solid Tumors (Phase 1), HNSCC | Phase 1 | Not yet recruiting | MEKanistic Therapeutics, Inc. | 71 | 2026-10-20 | 2026-10-15 |
| Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors QN-302 - Solid Tumor | Phase 1 | Recruiting | Qualigen Theraputics, Inc. | 54 | 2023-11-01 | 2024-05-01 |
| Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors Decoy20, Tislelizumab - Solid Tumor, Adult, HCC - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Indaptus Therapeutics, Inc | 120 | 2023-02-28 | 2026-01-13 |
| SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) SurVaxM - Newly Diagnosed Glioblastoma | Phase 2 | Unknown | MimiVax, LLC | 247 | 2021-11-18 | 2024-02-26 |
| NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab - Non-small Cell Lung Cancer | Phase 2 | Completed | NeoTX Therapeutics Ltd. | 38 | 2021-10-26 | 2025-03-03 |
| Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy STP705 - Hepatocellular Carcinoma, Liver Metastases | Phase 1 | Completed | Sirnaomics | 5 | 2021-03-01 | 2024-03-19 |
| Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer Ketogenic Diet - Metastatic Pancreatic Ductal Adenocarcinoma | Not applicable | Completed | Translational Drug Development | 32 | 2020-12-02 | 2025-02-21 |
| PK and Dose Escalation and Expansion Study of DST-2970 Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone) - Prostate Cancer | Phase 1 | Terminated | DisperSol Technologies, LLC | 26 | 2020-01-31 | 2024-10-17 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer GZ17-6.02, Capecitabine - Advanced Cancer, Gastric Cancer | Phase 1 | Unknown | Genzada Pharmaceuticals USA, Inc. | 127 | 2019-03-01 | 2022-12-23 |
| A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine misetionamide (also known as GP-2250) - Ovarian Cancer | Phase 1 | Recruiting | Persevere Therapeutics Inc. | 18 | 2019-01-14 | 2026-10-19 |
| Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies NP-G2-044 - Breast Cancer, Pancreas Cancer | Phase 1 | Completed | Novita Pharmaceuticals, Inc. | 23 | 2017-12-21 | 2025-07-20 |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Minnelide™Capsules - Advanced Cancer, Gastric Cancer | Phase 1 | Unknown | Minneamrita Therapeutics LLC | 66 | 2017-10-10 | 2023-10-18 |
| Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer biomarker study - Metastatic Breast Cancer | Not applicable | Completed | Side-Out Foundation | 28 | 2017-03-09 | 2020-07-01 |
| A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia Dociparstat sodium - Acute Myeloid Leukemia | Phase 1 | Completed | Jazz Pharmaceuticals | 12 | 2013-12-01 | 2023-02-21 |
| A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer treated recommended - Metastatic Breast Cancer | Not applicable | Completed | Translational Drug Development | 25 | 2013-08-01 | 2023-03-28 |
| Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients Nab paclitaxel, Gemcitabine, Dociparstat - Metastatic Pancreatic Cancer | Phase 2 | Terminated | Jazz Pharmaceuticals | 60 | 2011-11-01 | 2022-06-06 |
| A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank - Previously Treated Metastatic Pancreatic Cancer | Phase 2 | Completed | Translational Drug Development | 35 | 2010-09-01 | 2012-07-17 |
| Triple Negative Breast Cancer Biomarker Study Metastatic Breast Cancer, Triple Negative Breast Cancer | Completed | US Oncology Research | 14 | 2010-05-01 | 2013-07-23 | |
| Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca Approved therapy will be assigned based on molecular profile and RPMA results - Metastatic Breast Cancer | Early Phase 1 | Completed | Translational Drug Development | 28 | 2010-03-01 | 2023-09-28 |
Breast Neoplasms (7) · Pancreatic Neoplasms (6) · Colonic Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Carcinoma, Basal Cell (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1)
Gemcitabine (2) · N-desulfated,2-O,3-O-desulfated heparin (2) · Abiraterone Acetate (1) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Comparative Genomic Hybridization (1) · Diet, Ketogenic (1) · Docetaxel (1) · Injections (1) · NP-G2-044 (1) · Prednisone (1) · Taxes (1) · abiraterone (1) · naptumomab estafenatox (1) · obinutuzumab (1)
United States (18)
Daniel Von Hoff, MD (1) · Francois Lebel, MD (1) · Gayle Jameson, RNMSNACNP-BC (1) · Ilana Lorber, MD (1) · Jillian Zhang, Ph.D. (1) · John Carpten, PhD (1) · Jordan Jacobs, MBA (1) · Joyce A O'Shaughnessy, MD (1) · Kathryn Gazarik (1) · Manmeet S Ahluwalia, MD, MBA (1) · Michael Ciesielski, PhD (1) · Mitesh J Borad, MD (1) · Ramesh Ramanathan, MD (1) · Robert Fenstermaker, MD (1)
PMID 10318881, PMID 10623795, PMID 10725753, PMID 10766164, PMID 11221872, PMID 12070671, PMID 12135582, PMID 15758009, PMID 16582593, PMID 16731740, PMID 16918305, PMID 18056471, PMID 20231676, PMID 20422411, PMID 25209003, PMID 27576783, PMID 29540489, PMID 29921698, PMID 33188449, PMID 35276694, PMID 35425930, PMID 38758815, PMID 41707378, PMID 9422522, PMID 9858522